Drug Cost
CMS nixes 'most-favored nation' pricing model for Medicare Part B
CMS plans to rescind a Trump-era interim final rule that would have established a “most-favored nation” pricing model for Medicare Part B drugs, following months of lawsuits that saw the proposal stalled in federal court.
Cancer drug revenues increased by 96% over past decade
The oncology drug setting has changed monumentally in recent years, with an unprecedented increase in new therapeutic agents. This surge in drug development is reflected by a 70% increase in clinical trials for new cancer drugs.
Most-favored nation model for Medicare Part B drug reimbursement ‘designed to fail’
A new Trump administration policy aimed at lowering drug prices for Medicare beneficiaries has drawn criticism from the medical community, especially those in the oncology field.
ACR urges UnitedHealthcare to cancel new copay proposal
The American College of Rheumatology and 11 other provider and patient groups have called on UnitedHealthcare to cancel its proposed copay accumulator initiative, arguing it would increase financial burdens and limit access to treatments.
Should prices of biosimilars be regulated in the US?
Bringing down the prices of biosimilars in the United States will be a tricky balance. On one hand, you want to be able to make these drugs available to every patient who needs them. On the other hand, just lowering the prices artificially through legislation could stunt innovation and disincentivize companies from bringing these drugs to market.
Patients with lupus more likely to skip doses, delay filling prescriptions due to cost
Patients with systemic lupus erythematosus are more likely than those in the general population to skip doses, take less medicine and delay filling prescriptions due to cost, according to data published in Arthritis Care & Research.
Big pharma and COVID-19: Balancing social commitments and profits
It is quite possible that the attempt to treat COVID-19 will bear out as the peak of pharmaceutical research and development in human history.
Adding colchicine to prevent gout flares while initiating allopurinol 'very cost effective'
Despite its increased cost in the United States, colchicine use to prevent gout flares while starting treatment with allopurinol remains “very cost effective,” according to findings published in Arthritis Care & Research.
Bringing drug costs down a ‘peg’ or two
At our center, metrics obtained through our participation in CMS’s Oncology Care Model have allowed us to improve patient experience scores, reduce ED utilization and hospital admission, and impact several other measures of quality care.
Some patients turning to Craigslist for affordable insulin
People are using Craigslist to buy and sell lifesaving drugs, particularly insulin, according to a research letter published in JAMA Internal Medicine.